| Name | Title | Contact Details |
|---|
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company based in Roseville, Minnesota. Our mission is to address health challenges such as obesity, diabetes, high cholesterol and food allergies by developing healthier food ingredients that produce high-quality, convenient and delicious food, while also providing agriculturally advantageous crop traits to farmers. As a leader in our field, our team is positively changing the way Americans eat by pioneering a paradigm shift to help make the food you love a healthier choice™.
CombiMatrix Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
SimQuest is a Silver Spring, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.